These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 27645111)

  • 41. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
    Jacobson TA
    Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The tolerability and efficacy of low-dose simvastatin in statin-intolerant patients.
    Degreef LE; Opdam FL; Teepe-Twiss IM; Jukema JW; Guchelaar HJ; Tamsma JT
    Eur J Intern Med; 2010 Aug; 21(4):293-6. PubMed ID: 20603038
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins.
    Barter PJ; Rye KA
    Circulation; 2006 Sep; 114(12):1315-20; discussion 1320. PubMed ID: 16982953
    [No Abstract]   [Full Text] [Related]  

  • 44. The genetic determinants of atorvastatin response.
    Rodrigues AC; Hirata MH; Hirata RD
    Curr Opin Mol Ther; 2007 Dec; 9(6):545-53. PubMed ID: 18041665
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gitelman's syndrome presenting as intolerance to statin therapy.
    Freedman DB; Housley D
    Ann Clin Biochem; 2005 May; 42(Pt 3):232-3. PubMed ID: 15949161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statin-related myotoxicity.
    Fernandes V; Santos MJ; Pérez A
    Endocrinol Nutr; 2016 May; 63(5):239-49. PubMed ID: 27005745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NLA Task Force on Statin Safety--2014 update.
    Jacobson TA
    J Clin Lipidol; 2014; 8(3 Suppl):S1-4. PubMed ID: 24793438
    [No Abstract]   [Full Text] [Related]  

  • 49. Algorithms to Identify Statin Intolerance in Medicare Administrative Claim Data.
    Colantonio LD; Kent ST; Huang L; Chen L; Monda KL; Serban MC; Manthripragada A; Kilgore ML; Rosenson RS; Muntner P
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):525-533. PubMed ID: 27389413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.
    Mohassel P; Mammen AL
    Muscle Nerve; 2013 Oct; 48(4):477-83. PubMed ID: 23519993
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
    Filardi PP; Paolillo S; Trimarco B
    G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of statin-intolerant patient.
    Arca M; Pigna G; Favoccia C
    Panminerva Med; 2012 Jun; 54(2):105-18. PubMed ID: 22525565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Narrative review: statin-related myopathy.
    Joy TR; Hegele RA
    Ann Intern Med; 2009 Jun; 150(12):858-68. PubMed ID: 19528564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advances in the management of statin myopathy.
    Gallo A; Perregaux J; Bruckert E
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):142-151. PubMed ID: 33278129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk.
    Müller-Wieland D; Assmann G; Carmena R; Davignon J; von Eckardstein A; Farinaro E; Greten H; Olsson AG; Riesen WF; Shlyakhto E
    Eur J Prev Cardiol; 2016 Feb; 23(3):275-81. PubMed ID: 25595550
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy.
    Joseph L; Robinson JG
    Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strategies to overcome statin intolerance.
    Agouridis AP; Nair DR; Mikhailidis DP
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Beyond lowering LDL cholesterol].
    Bayturan O; Utük O; Tuzcu EM
    Anadolu Kardiyol Derg; 2011 Mar; 11(2):163-7. PubMed ID: 21342860
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statin Intolerance From a Clinician's Perspective.
    Whayne TF
    Angiology; 2016 Mar; 67(3):205-7. PubMed ID: 26019266
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.